


FGFR4-IN-1

Cat. No.:	HY-100631		
CAS No.:	1708971-72-5		
Molecular Formula:	C ₂₄ H ₂₇ N ₇ O ₅		
Molecular Weight:	493.52		
Target:	FGFR		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.4 mg/mL (12.97 mM; Need warming)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0263 mL	10.1313 mL	20.2626 mL
	5 mM	0.4053 mL	2.0263 mL	4.0525 mL
	10 mM	0.2026 mL	1.0131 mL	2.0263 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	FGFR4-IN-1 is a potent inhibitor of FGFR4 with IC ₅₀ of 0.7 nM.
IC ₅₀ & Target	FGFR4 0.7 nM (IC ₅₀)
In Vitro	FGFR4-IN-1 significantly inhibits the proliferation of HuH-7 hepatocellular carcinoma cells with IC ₅₀ of 7.8 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay^[1]

Methylene blue staining proliferation assay (MBS): The effect of compounds on cell proliferation is assessed using HuH-7 hepatocellular carcinoma cells are cultured in the vendor-recommended medium. Specifically, 5000 cells/well are seeded in 96-well tissue culture plates in a total media volume of 100 µL/well and increasing compound dilutions or DMSO are added

24 hours thereafter in triplicates. 72 hours after compound addition, cells are fixed by adding 25 and incubated for 10 minutes at room temperature. Cells are washed three times with H₂O. Cells are washed 3 times with H₂O, 200 mL/well and then lysed by adding 200 mL/well of 3% HCl for 30 minutes at room temperature with shaking. Optical density is measured at A650 nm. The concentration of compound providing 50% of proliferation inhibition with respect to DMSO-treated cells is determined (IC₅₀) using XLFit software.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO 2015059668 A1?

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA